GSK Annual Report 2011 133 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Dr Moncef Slaoui is a member of the US Retirement Savings Plan, a Basis of preparation 401k savings scheme open to all US employees and the Executive Supplemental Savings Plan, a savings scheme open to executives to The Remuneration Report has been prepared in accordance with the Companies Act 2006 and The Large and Medium-sized accrue benets above US government limits imposed on the Retirement Savings Plan.
Contributions to both plans are invested in Companies and Groups Accounts and Reports Regulations 2008 the Regulations and meets the relevant requirements of the FSA a range of funds and the value of the accumulated funds is paid Listing Rules.
In accordance with the Regulations, the following at retirement.
sections of the Remuneration Report are subject to audit: Directors During 2011, contributions of $122,450 76,056 were paid into emoluments and total remuneration, Non-Executive Directors fees, these two schemes by GSK in respect of Dr Moncef Slaoui.
Long-Term Incentive plans including Share Option Plan awards, Deferred Annual Bonus Plan awards, Performance Share Plan Directors interests in contracts awards and Share Value Plan awards and Pension benets for Except as described in Note 35 to the financial statements, Related which the opinion thereon is expressed on page 135.
The party transactions, during or at the end of the financial year no remaining sections are not subject to audit nor are the pages Director or connected person had any material interest in any referred to from within the audited sections.
The Remuneration contract of signicance with a Group company.
Report has been approved by the Board of Directors and signed on its behalf by Directors and Senior Management Further information is provided on compensation and interests of Directors and Senior Management as a group the group.
For this purpose, the group is dened as the Non-Executive and Executive Directors, other members of the CET and the Company Secretary.
For the financial year 2011, the total compensation Sir Crispin Davis paid to members of the group for the periods during which they Remuneration Committee Chairman served in that capacity was 24,390,535, the aggregate increase 9 March 2012 in accrued pension benets, net of ination, was 820,847 and the aggregate payment to dened contribution schemes was 666,224.
During 2011, the members of the group were awarded 63,090 shares and 34,799 ADS under the Deferred Annual Bonus Plan, 1,482,920 shares and 389,088 ADS under the Performance Share Plan, and 10,050 shares and 2,450 ADS under the Share Value Plan.
No options were granted to members of the group under the Share Option Plan in 2011.
No notional shares or ADS were granted under the Deferred Investment Award Plan in 2011.
Members of the group were awarded, through the reinvestment of dividends, 173,842 shares and 50,214 ADS in the Performance Share Plan, 2,818 shares and 855 ADS in the Deferred Annual Bonus Plan and 7,390 notional shares in the Deferred Investment Award Plan.
At 2 March 2012, the group comprising 32 persons owned 1,455,671 shares and 305,139 ADS, constituting less than 1% of the issued share capital of the company.
The group also held, at that date: options to purchase 3,006,151 shares and 450,253 ADS: 3,441,501 shares and 910,171 ADS awarded under the Performance Share Plan, including those shares and ADS that are vested and deferred: 1,421 vested and deferred ADS under the legacy SmithKline Beecham Mid-Term Incentive Plan: 26,607 shares and 3,090 ADS awarded under the Share Value Plan: 91,853 shares and 36,071 ADS under the Deferred Annual Bonus Plan and 127,596 notional shares awarded under the Deferred Investment Award Plan.
These holdings were issued under the various executive share plans described in Note 42 to the financial statements, Employee share schemes.
